

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/G095A39317A7EN.html>

Date: August 2022

Pages: 69

Price: US\$ 3,500.00 (Single User License)

ID: G095A39317A7EN

Abstracts

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) pipeline Target constitutes close to 10 molecules, which are developed by Companies. The latest report Growth Differentiation Factor 8 - Drugs In Development, 2022, outlays comprehensive information on the Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Myostatin also known as growth differentiation factor 8 or GDF-8 is a myokine a protein produced and released by myocytes. This protein is part of the transforming growth factor beta (TGF?) superfamily. Myostatin is found almost in muscles used for movement, where it is active both before and after birth. This protein normally restrains muscle growth, ensuring that muscles do not grow too large. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 2, 2 and 2 respectively. Report covers products from therapy areas Central Nervous System, Musculoskeletal Disorders, Genetic Disorders, Hematological Disorders and Oncology which include indications Spinal Muscular Atrophy (SMA), Duchenne Muscular

Dystrophy, Alpha Thalassaemia, Amyotrophic Lateral Sclerosis, Anemia, Becker Muscular Dystrophy, Beta Thalassaemia, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Limb-Girdle Muscular Dystrophy, Muscle Wasting Disorders, Myelodysplastic Syndrome, Myelofibrosis, Neuromuscular Disorders, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF) and Sarcopenia.

Furthermore, this report also reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)

The report reviews Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics and enlists all their major and minor projects

The report assesses Growth/Differentiation Factor 8 (Myostatin or GDF8 or

MSTN) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Overview

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Companies Involved in
Therapeutics Development

Accelaron Pharma Inc

Biogen Inc

Biohaven Pharmaceutical Holding Company Ltd

Bioleaders Corp

Chugai Pharmaceutical Co Ltd

Genentech USA Inc

PeptiDream Inc

Pfizer Inc

Regeneron Pharmaceuticals Inc

Scholar Rock Inc

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Drug Profiles
apitegromab - Drug Profile

Product Description

Mechanism Of Action

History of Events

BIIB-110 - Drug Profile

Product Description

Mechanism Of Action

History of Events

BLSM-22 - Drug Profile

Product Description

Mechanism Of Action

History of Events

domagrozumab - Drug Profile

Product Description

Mechanism Of Action

History of Events

Iuspatercept - Drug Profile

Product Description

Mechanism Of Action

History of Events

Monoclonal Antibody to Inhibit Myostatin for Spinal Muscular Atrophy - Drug Profile

Product Description

Mechanism Of Action

History of Events

Myostatin antagonist - Drug Profile

Product Description

Mechanism Of Action

History of Events

RG-6237 - Drug Profile

Product Description

Mechanism Of Action

History of Events

talditercept alfa - Drug Profile

Product Description

Mechanism Of Action

History of Events

trevogrumab - Drug Profile

Product Description

Mechanism Of Action

History of Events

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Dormant Products

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Discontinued Products

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Product Development
Milestones

Featured News & Press Releases

Jul 08, 2022: Biohaven enrolls first subject in Phase III spinal muscle atrophy trial

Jul 01, 2022: Scholar Rock to present phase 3 SAPPHIRE trial design at the 17th
International Congress on Neuromuscular Diseases (ICNMD 2022)

Jun 17, 2022: Positive phase 2 Topaz trial extension data demonstrate sizable and

sustained motor function improvement at 24 months with apitegromab for non-ambulatory patients with types 2 and 3 spinal muscular atrophy (SMA)

Jun 09, 2022: Scholar Rock to Present New Apitegromab Data Including 24-Month Efficacy and Safety Data from TOPAZ Phase 2 Trial at the 2022 Annual Cure SMA Conference

Jun 03, 2022: Bristol Myers Squibb withdraws supplemental biologics license application (sBLA) for Reblozyl (luspatercept-aamt) for non-transfusion dependent (NTD) beta thalassemia

Apr 21, 2022: Scholar Rock presents data analysis of multiple efficacy endpoints from the Apitegromab TOPAZ Phase 2 Trial at the 2022 European Paediatric Neurology Society Congress

Mar 25, 2022: Bristol Myers Squibb announces new Prescription Drug User Fee Act goal date for Reblozyl (luspatercept-aamt) supplemental biologics license application

Mar 22, 2022: Scholar Rock presents data analysis of multiple efficacy endpoints from the apitegromab TOPAZ phase 2 trial at the American Academy of Neurology 2022 Annual Meeting

Mar 13, 2022: Scholar Rock to present data from TOPAZ Ambulatory Cohort Analysis at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Dec 03, 2021: U.S. Food and Drug Administration accepts for priority review supplemental biologics license application for Reblozyl (luspatercept-aamt) in adults with non-transfusion dependent (NTD) beta thalassemia

Nov 30, 2021: Scholar Rock announces design of phase 3 SAPPHIRE clinical trial evaluating apitegromab in non-ambulatory patients with Type 2 and Type 3 spinal muscular atrophy (SMA)

Oct 03, 2021: Scholar Rock to present Apitegromab TOPAZ phase 2 pharmacologic data at the 2021 World Congress of Neurology

Sep 30, 2021: Scholar Rock presents exploratory responder analysis on efficacy data from the apitegromab TOPAZ phase 2 trial at the Child Neurology Society Annual Meeting

Sep 23, 2021: Scholar Rock presents additional data analyses from the Apitegromab TOPAZ phase 2 trial at the World Muscle Society 2021 Virtual Congress

Sep 07, 2021: Therapeutic Goods Administration provides update on Reblozyl

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Acceleron Pharma Inc, 2022

Pipeline by Biogen Inc, 2022

Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2022

Pipeline by Bioleaders Corp, 2022

Pipeline by Chugai Pharmaceutical Co Ltd, 2022

Pipeline by Genentech USA Inc, 2022

Pipeline by PeptiDream Inc, 2022

Pipeline by Pfizer Inc, 2022

Pipeline by Regeneron Pharmaceuticals Inc, 2022

Pipeline by Scholar Rock Inc, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/G095A39317A7EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G095A39317A7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970